NIDDK's O'Brien Urology Centers Reopen After Six Years: $5.2M, One February 1 Deadline, and No Second Chance
November 15, 2026 · 7 min read
Granted Research Team · Editorial policy
Non-cancer urologic conditions such as incontinence, kidney stones, urinary tract infections, chronic pelvic pain, benign prostate disease, and erectile dysfunction cost Americans at least $11.5 billion a year to treat, according to NIDDK. They get a small fraction of the research money that urologic cancers attract. NIDDK's main tool for closing that gap is the George M. O'Brien Urology Cooperative Research Centers Program, and it is now open to new applicants for the first time since 2020.
RFA-DK-28-314 (U54, Clinical Trial Optional) posted on November 3, 2026, as a reissue of RFA-DK-20-008. NIDDK plans to commit $5.2 million in total costs in FY2027. Grants.gov lists five anticipated awards, and each application is expected to budget about $750,000 in direct costs per year for up to five years. There is one receipt date, February 1, 2027, at 5:00 p.m. local time, for new, renewal, and resubmission applications. The submission window opens January 1, and the NOFO expires February 2.
An applicant that misses the date, or is triaged in July, does not get a second try in June. The prior competition opened in 2020. This one is the competition for the next five years.
A Network, Not Just a Grant
The O'Brien Centers are one part of an NIDDK network called CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology). CAIRIBU links the U54 centers, a U24 Urology Centers Program Interactions Core based at the University of Wisconsin–Madison (renewed in 2025), smaller exploratory Urology P20 Centers, and two institutional career-development programs: the KURe K12 in urologic research and the UroEpi K12 in urologic epidemiology. NIDDK's advisory council approved the concept to continue the U54 centers and the Interactions Core in May 2024. This NOFO carries out that decision.
Membership comes with duties. Every funded center must take part in all CAIRIBU activities, including the annual CAIRIBU meeting. Each center must work with the Interactions Core on the CAIRIBU Opportunity Pool Program, helping to identify candidates, collaborate with awardees, and review applications. Each must also show how it serves "the broader national urology research community," not only its own investigators. Reviewers score how the proposed center "will increase the research capability of the larger urology research community." Leave that out and the application loses points on Significance.
CAIRIBU's center roster includes Stanford, whose current award runs from 2021 to 2026, and long-running centers at Columbia and the University of Wisconsin. With the 2020-cycle awards ending, expect incumbents to compete for renewal. Renewals are judged on progress made in the last funding period. A new applicant is competing against incumbents who can point to five years of shared resources and papers.
How a Center Has to Be Built
The NOFO is unusually specific about structure, and much of the triage will happen here.
| Component | Required? | Page limit | Count |
|---|---|---|---|
| Overall | Required | 6 | 1 |
| Administrative Core (includes Educational Enrichment Program) | Required | 6 | 1 |
| Biomedical Research Core | Optional | 6 | 0–1 |
| Research Projects | Required | 12 each | 2–3 |
A viable center needs the Administrative Core plus at least three highly meritorious components: either two Research Projects and a Biomedical Research Core, or three Research Projects. If one project is weak, a two-project center with no core falls below that minimum. A third project or a strong core gives you a margin.
The other structural rules:
- A urologist has to do real science on the team. At least one Research Project must include "a clinical urology expert with demonstrated involvement in the proposed science (i.e., beyond simply recruiting patients or providing patient biosamples)." Either the Center Director or an Associate Director must have strong clinical urology expertise, unless a Project Leader already provides it.
- The Center Director does not need a urology background. This is the opening for outsiders. An immunologist, microbiome scientist, bioengineer, or machine learning researcher with "an established record of external funding and research accomplishment" can lead the center if the clinical urology expertise sits elsewhere in the leadership.
- The projects must use more than one approach. Together they must include at least two of the three: clinical studies or trials, translational research, and basic science.
- Both sexes must be studied. Projects should address questions in both males and females unless there is a strong justification. This applies even to prostate and erectile dysfunction work at the center level, so plan a portfolio that includes female pelvic floor, bladder, or UTI research.
- The Biomedical Research Core must serve the field. NIDDK will favor "innovative, high-value cores beyond those typically found at a research institution." Its examples include sample and data repositories, specialized technologies, validated patient-reported genitourinary symptom measures, standardized reagents and protocols, and coordinated recruitment. A standard histology or imaging core will not compete.
- The Educational Enrichment Program cannot pay stipends or tuition. It is meant for seminars, summer programs, and workshops that bring students, fellows, and junior faculty into benign urology. The environment criterion asks about institutional commitment, including "additional financial support for co-funded activities like the Educational Enrichment Program." A dean's letter promising matching money for the program helps.
What Gets an Application Returned Unreviewed
Three kinds of work are non-responsive and will be returned without review:
- Studies of malignant genitourinary disease, meaning anything about cancer.
- Studies of "biological changes primarily affecting the kidney in the absence of clinical genitourinary considerations." Pure nephrology belongs in NIDDK's kidney programs, not here.
- Studies "without a potential to inform improved clinical management or clinical trial design."
The third rule matters most. It does not ban basic science, since basic studies are one of the three allowed approaches. It does mean every project needs a believable line from mechanism to clinic. The Overall Research Strategy must give "a rationale for how the proposed studies may ultimately inform the evidence base for improved clinical management." A project on urothelial barrier biology passes if it names the patient phenotype it could eventually stratify, such as interstitial cystitis/bladder pain syndrome subtypes or recurrent UTI. Without that, it is at risk.
The NOFO lists priority areas: lower urinary tract symptoms, chronic pelvic pain, UTIs, urologic stones, bladder and prostate disorders, erectile dysfunction, and congenital urinary and reproductive anomalies. It explicitly encourages cross-cutting approaches like regenerative medicine, AI/machine learning, and microbiome research, plus expertise from outside traditional urology. It also points applicants to the NIDDK Central Repository for existing samples and data, including cohorts from the MAPP and LURN networks. Using those resources is a cheap way to show feasibility and to reuse what NIDDK has already paid for.
Rules That Are New Since 2020
Even renewing centers will find several requirements that did not exist in the last competition:
- Letters of Collaboration replace Letters of Support (NOT-OD-26-094). The narrative carries the weight, and the letters are optional confirmations of specific arrangements. Do not attach a stack of general endorsements.
- Clinical trial activation and enrollment metrics. If the center runs any interventional trial, it must report milestone dates for activation and enrollment each year in the RPPR. NIDDK will calculate standardized startup and accrual intervals from them. If your institution's IRB and contracting take six months to activate a trial, that will show up in the numbers.
- The HHS policy terms now in every NIH NOFO. These include the prohibition on funding race-based selection criteria, the "biological and physiological integrity" emphasis on accounting for sex, and a statement that NIH "prioritizes" rigorous methods and populations with limited access to care. For a program that already requires studying both sexes, the sex language fits easily. Describe sex as a biological variable in the study design and you address both the NOFO and the policy term.
- Indirect costs follow the old rule. The FY2026 appropriations act keeps the 45 CFR 75 indirect cost provisions for NIH. Budget at your negotiated rate.
One small error is worth knowing about. The funding paragraph says the $5.2 million supports "applications responding to RFA-DK-27-128," which looks like a leftover from a draft. Submit to RFA-DK-28-314 through ASSIST, and if your sponsored programs office notices the mismatch, a short email to NIDDK_KUH@nih.gov will settle it.
An 11-Week Plan
From mid-November to February 1 is about eleven weeks. That is tight for a four-to-six-component U54, and the holidays fall in the middle of it.
This week: Email NIDDK's Division of Kidney, Urologic, and Hematologic Diseases (NIDDK_KUH@nih.gov) with a one-page concept. The NOFO asks applicants to make this contact before submitting. Program staff will tell you whether the science fits and whether your planned core duplicates something an incumbent already offers nationally.
By December 1: Lock in leadership. Confirm the Center Director's funding record, name the clinical urologist and their specific scientific role, and decide whether you will propose two projects plus a core or three projects. If anyone on the team is a current Urology P20 PD/PI, be aware that the P20 award ends if the U54 is funded. That is often a good trade, but say so explicitly.
By mid-December: Draft the Specific Aims for every Research Project and a one-page Overall framework explaining why "the Center as a whole is greater than the sum of its parts," which the NOFO asks for in those words. Line up any External Advisory Committee expertise, but do not name members in a new application.
January: Write the full application, the Data Management and Sharing Plan, and the Resource Sharing Plan. Get the institutional commitment letter for space, protected time, and Educational Enrichment co-funding. Follow the Multi-Project (M) instructions exactly, because multi-component applications are where ASSIST validation errors pile up. Plan to submit by January 25 so there is time to fix them.
Peer review is scheduled for July 2027, advisory council for October 2027, and the earliest start date is December 2027.
With one receipt date and five slots in a five-year cycle, a urology research group's best chance is an application that is finished early. Granted can help you assemble a multi-component center application, from the Overall narrative to each project's Specific Aims, well ahead of the February 1 date.